CIMZIA is available under pharmacy and medical benefits in 2 formulations
Click to enlarge
CIMZIA is administered by subcutaneous injection. There are two ways to administer CIMZIA.
The recommended loading dose of CIMZIA for adults with moderate to severe CD is
400 mg (given as 2 subcutaneous injections of 200 mg) initially and at weeks 2 and
4. In patients who obtain a clinical response, the recommended maintenance regimen
is 400 mg every 4 weeks.
Rare reports of blood dyscrasias have been reported with CIMZIA; patients should
be advised to seek medical attention if they develop.
Concurrent administration of CIMZIA with certain biological DMARDs, including anakinra,
abatacept and rituximab, is not recommended due to an increased risk of serious infections.
In pre-marketing controlled trials of all patient populations combined the most
common adverse reactions (≥8%) were upper respiratory infections (18%), rash (9%)
and urinary tract infections (8%).
NEXT: In-Office Administration »
CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had inadequate response to conventional therapy.
IMPORTANT SAFETY CONSIDERATION
Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.
For more information 1-866-4-CIMZIA (1-866-424-6942)
*Not valid for prescriptions that are reimbursed, in whole or part, including Medicare Part D, Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico) or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, Tricare, VA and DoD) for reimbursement. Patients and pharmacists are responsible for notifying insurance carriers or other third party who pays for or reimburses any part of the prescription filled using this card as may be required by the insurance carrier's terms and conditions and applicable law. Other restrictions may apply. In 2013, over 97% of CIMZIA Co-Pay Card claims resulted in no out-of-pocket costs for those program participants.
For US Healthcare Professionals
© 2014 UCB, Inc. All rights reserved.CZP-PRM-015320-0114B
OXO, Good Grips® and the associated logos are registered trademarks of Helen of Troy Limited and are used under license.
CIMZIA® and CIMplicity® are registered trademarks, and the cimplicity™ logo is a trademark, of the UCB Group of Companies.
Trademarks of products listed are the property of their respective owners.